TRANSMEDICS GROUP INC
TMDXNASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $60.11 โ $156.00
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 34.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- 15.3
- P/S Ratio
- 3.5x
- EPS (TTM)
- $3.73
- Dividend Yield
- โ
TRANSMEDICS GROUP INC
TMDXFinancial history unavailable.
About TRANSMEDICS GROUP INC
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.